

Name of Entity: Zenitas Healthcare Limited
ABN: 78 009 074 588
Reporting Period: Financial Year ended 30 June 2018
Previous Corresponding Period: Financial Year ended 30 June 2017

Results for Announcement to the Market

	FY 2018 \$	FY 2017 \$	Change from FY 2017
Revenue from continuing operations	76,562,586	22,396,650	242%
Profit/(Loss) after tax from continuing operations attributable to members	3,881,468	(669,238)	680%
Earnings (Loss) per share*	6.1	(0.4)	1625%
Net tangible assets per share (cents)	(15.10)	5.49	(375%)
* Weighted Average Number of Issued Shares	63,693,628	167,287,699	

Dividends

The Directors have recommended the payment of a 100% franked final dividend of \$0.015 (1.5 cents) per fully paid ordinary share to be paid on 17 October 2018 in respect of the financial year ended 30 June 2018.

The final dividend will be paid to all shareholders on the register of members as at the Record Date of 19 September 2018. The dividend has not been included as a liability in the financial statements.

In April 2018, an unfranked interim dividend of \$0.01 (1 cent) per fully paid ordinary share valued at \$742,737 was paid. The record date was 19 March 2018 and the payment date was 16 April 2018.

Consolidated Financial Statements

Other information requiring disclosure to comply with ASX Listing Rule 4.3A is contained in, and should be read in conjunction with, the notes to the Consolidated Financial Statements and the Directors' Report for the year ended 30 June 2018.

The financial report is based on the Consolidated Financial Statements which have been audited by RSM Australia Partners.

The company's Annual General Meeting is to be held on Friday, 23 November 2018 with details to be communicated to shareholders in due course.

Review of Operations

Highlights of the results for the year ended 30 June 2018 included:

- Underlying FY18 EBITDA of \$13.9m, \$6.9m higher than FY17 proforma EBITDA of \$7.0m.
- Underlying FY18 EBITDA excluding material acquisitions of \$13.2m, in line with previous guidance provided of between \$13.0m and \$13.5m.
- Underlying EBITDA margin of 18.2%, up 12% compared to FY17 proforma EBITDA margin.
- The Company's balance sheet remains sound with cash at year-end of \$6.7m and undrawn debt facilities of \$6.5m.
- Completion of the acquisition of 13 community-based healthcare businesses.
- Full year revenues up by \$54.2m to \$76.6m, a significant increase from FY17 as a result of the full-year contribution from previous acquisitions and the Acquisitions completed during the year.
- Successful completion of a \$30 million placement and rights issue capital raising in October 2017.
- The successful integration of the Acquisitions into the Group.
- Continued focus on organic growth initiatives including increased capture of cross-referrals, 55,000+ new patients and clients, 6% increase in Residential Aged Care Facility beds serviced, and the roll-out of existing services into existing and new locations.
- The continued assessment of investment and acquisition opportunities in order to fulfil the Group's vision of becoming the leading ASX-listed community-based healthcare service provider.

Summary Results for the Year Ended 30 June 2018

	2018	2017	Change from 2017
	\$	\$	%
Revenue from continuing operations	76,562,586	22,396,650	242%
Underlying Earnings before interest, tax, depreciation and amortisation (EBITDA)	13,914,055	3,453,663	303%
Acquisition and Non-Operating Expenses	(1,857,820)	(2,294,495)	19%
EBITDA	12,056,235	782,507	1440%
Depreciation and Amortisation	(1,651,530)	(790,399)	(109%)
Earnings before interest and tax (EBIT)	10,404,705	(7,892)	131939%
Net Interest Income/(Expense)	(799,291)	(56,151)	(1323%)
Profit Before Tax	9,605,414	(64,043)	15098%
Tax Expense/(Benefit)	2,288,518	(229,659)	(1096%)
Profit/Loss after tax	7,316,896	165,616	4318%
Non-controlling interests	(3,435,428)	(834,854)	(312%)
Profit/Loss after tax after non-controlling interests	3,881,468	(669,238)	680%